Dr. Markman on Gynecologic Cancer Molecular Testing

Maurie Markman, MD, senior vice president for Clinical Affairs and National Director for Medical Oncology, Cancer Treatment Centers of America, Eastern Regional Medical Center, discusses the role of molecular testing in gynecologic cancers.

The role of molecular testing in gynecologic cancers is in its infancy. Markman believes that it is reasonable to use molecular testing on a patient who has failed standard therapy in order to provide a treatment option that was not previously considered.

In the future, Markman says, there will be drugs that are approved by the FDA for purposes not specifically related to gynecologic cancers. These agents would show value in gynecologic cancers because of molecular testing. Markman says that though this is a complicated area, it is evolving and represents the future in the disease.